In patients with arterial disease, low baseline diastolic blood pressure may correspond with increased progression of subcortical atrophy, researchers reported online ahead of print June 10 in JAMA Neurology. The association may not depend on subsequent change in blood pressure. Researchers measured blood pressure for 663 participants at baseline and at a mean of 3.9 years later. Change in brain parenchymal fraction, cortical gray matter fraction, and ventricular fraction were quantified as indicators of progression of global, cortical, and subcortical brain atrophy. Patients with lower baseline diastolic blood pressure or mean arterial pressure had more progression of subcortical atrophy. Of patients with higher baseline blood pressure, those with declining blood pressure over time had less progression of subcortical atrophy, compared with those with increasing blood pressure.

Diffusion tensor imaging (DTI) of the basal ganglia and cerebellum may accurately diagnose Parkinson’s disease and other movement disorders, according to a study published online ahead of print May 14 in Movement Disorders. Investigators studied 72 subjects with DTI at 3 T. The technique distinguished between controls and patients with movement disorder with 92% sensitivity and 88% specificity. DTI also distinguished between controls and patients with parkinsonism (93% sensitivity, 91% specificity), Parkinson’s disease and atypical parkinsonism (90% sensitivity, 100% specificity), Parkinson’s disease and multiple system atrophy (94% sensitivity, 100% specificity), Parkinson’s disease and progressive supranuclear palsy (87% sensitivity, 100% specificity), multiple system atrophy and progressive supranuclear palsy (90% sensitivity, 100% specificity), and Parkinson’s disease and essential tremor (92% sensitivity, 87% specificity).

Heading a soccer ball may be associated with abnormal white matter microstructure and poor neurocognitive performance, according to research published online ahead of print June 11 in Radiology. Thirty-seven amateur soccer players answered a questionnaire about heading in the previous 12 months and lifetime history of concussions. Investigators performed diffusion-tensor MRI on the players and evaluated their cognitive function. The players had headed a median of 432 times during the previous year. Heading was associated with lower fractional anisotropy (FA) at three locations in temporo-occipital white matter with a threshold that varied according to location. Heading more than 1,800 times per year was associated with lower levels of FA and poorer memory scores. Concussion history and demographic features were not significantly associated with FA or cognitive performance.

Restless legs syndrome (RLS) may entail an increased risk of mortality, independent of known risk factors, according to a study published online ahead of print June 12 in Neurology. Researchers conducted a prospective cohort study of 18,425 American men without diabetes, arthritis, or renal failure. RLS was assessed using standardized questions. During eight years of follow-up, 2,765 deaths occurred. In an age-adjusted model, RLS was associated with a 39% increased risk of mortality. The association between RLS and mortality was slightly attenuated after further adjustment for BMI, lifestyle factors, chronic conditions, sleep duration, and other sleep-related disorders. When patients with major chronic conditions (eg, cancer, high blood pressure, cardiovascular disease, and other comorbidities) were excluded, the adjusted hazard ratio for RLS was 1.92.

Patients with stroke who are about to undergo surgery can safely continue to take aspirin or warfarin in many instances, according to a guideline published in the May 28 Neurology. Researchers systematically reviewed the literature to assess evidence about the periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. Stroke patients undergoing dental procedures should routinely continue aspirin, according to the guideline. Stroke patients undergoing invasive ocular anesthesia, cataract surgery, dermatologic procedures, transrectal ultrasound–guided prostate biopsy, spinal or epidural procedures, and carpal tunnel surgery should probably continue aspirin. Stroke patients requiring warfarin should routinely continue it when undergoing dental procedures and probably continue it for dermatologic procedures. Some patients undergoing EMG, prostate procedures, inguinal herniorrhaphy, and endothermal ablation of the great saphenous vein should possibly continue warfarin.

Exposure to pesticides or solvents could be a risk factor for Parkinson’s disease, investigators concluded in the May 28 Neurology. Researchers performed a meta-analysis of prospective cohort and case-control studies that estimated the risk of Parkinson’s disease associated with exposure to pesticides or solvents. Parkinson’s disease was associated with farming, and the association between the disease and pesticides was highly significant in the studies in which Parkinson’s disease diagnosis was self-reported. In high-quality case-control studies, exposure to any pesticides, herbicides, and solvents increased the risk of Parkinson’s disease. Exposure to paraquat or maneb/mancozeb was associated with about a twofold increase in risk. Study quality was not a source of heterogeneity among prospective studies. In case-control studies, study quality was a source of heterogeneity in risk estimates for some exposures.

Atrial fibrillation may be associated with faster cognitive decline, according to a study published online ahead of print June 5 in Neurology. Researchers studied 5,150 men and women 65 or older who did not have atrial fibrillation or a history of stroke at baseline. Atrial fibrillation was identified by examining hospital discharge records and annual ECGs. A total of 552 patients (10.7%) developed incident atrial fibrillation during a mean seven years of follow-up. Mean Modified Mini-Mental State Examination (MMMSE) scores declined faster in patients with incident atrial fibrillation than in patients without atrial fibrillation. The predicted five-year decline in mean MMMSE score from age 80 to age 85 was −6.4 points for participants without atrial fibrillation and −10.3 points for participants with incident atrial fibrillation at age 80.

The level of interleukin 17F (IL-17F) in a patient with relapsing-remitting multiple sclerosis (MS) may not predict his or her response to treatment with interferon beta, according to research published online ahead of print June 3 in JAMA Neurology. Researchers analyzed serum samples from 239 randomly selected patients treated with interferon beta-1b (250 μg) for at least two years. Using clinical and MRI criteria, the investigators found that levels of IL-17F measured at baseline and month six did not correlate with lack of response to treatment after two years. Relapses and new lesions on MRI were not associated with pretreatment serum IL-17F levels. The results did not change when patients with neutralizing antibodies were excluded. Patients with levels of IL-17F higher than 200 pg/mL had poor response and clinical or radiologic activity.

Earlier treatment with thrombolytics may be associated with reduced mortality for patients with stroke, according to data published in the June 19 JAMA. Researchers analyzed data from 58,353 patients with acute ischemic stroke who were treated with t-PA within 4.5 hours of symptom onset in 1,395 hospitals. Patients’ median age was 72, 50.3% of patients were women, and median time to treatment was 144 minutes. A total of 5,142 in-hospital deaths occurred. Faster time to treatment, in 15-minute increments, was associated with reduced in-hospital mortality, reduced symptomatic intracranial hemorrhage, increased achievement of independent ambulation at discharge, and increased discharge to home. Patient factors most strongly associated with shorter time to treatment included greater stroke severity, arrival by ambulance, and arrival during regular hours.

High serum iron levels may be associated with a decreased risk of developing Parkinson’s disease, according to a study published June 4 in PLOS Medicine. Researchers investigated three polymorphisms in the genes HFE and TMPRSS6. For each polymorphism, they performed a meta-analysis of studies investigating the genetic effect on iron levels and a meta-analysis of studies investigating the genetic effect on the risk of Parkinson’s disease. Using three Mendelian randomization analyses, the investigators estimated the effect of iron on Parkinson’s disease for the three polymorphisms. Every 10 µg/dl increase in blood iron corresponded to a 3% reduction in the risk of Parkinson’s disease. Thus, increased blood iron levels may have a protective effect against Parkinson’s disease, but the underlying mechanism remains unclear, said the researchers.

Diabetes and dementia may have a bidirectional association, according to research published online ahead of print June 10 in JAMA Internal Medicine. Investigators examined 783 older adults with diabetes who were participating in a prospective population-based study. Subjects’ mean age was 74, and their baseline Modified Mini-Mental State Examination scores were 80 or higher. Approximately 47% of subjects were African American, and 47% were female. During the 12-year follow-up, 61 participants had a reported hypoglycemic event, and 148 developed dementia. Subjects who had a hypoglycemic event had a twofold increased risk for developing dementia, compared with those who did not have a hypoglycemic event. Subjects with diabetes who developed dementia had a greater risk for having a subsequent hypoglycemic event, compared with participants who did not develop dementia.

Cardiovascular biomarkers may help identify patients with subclinical cerebral injury, according to research published online ahead of print May 9 in Stroke. A total of 1,920 subjects received a brain MRI and had their levels of N-terminal brain natriuretic peptide (NT-proBNP) and cardiac troponin T (hs-cTnT) measured. Of the total group, 1,112 had a follow-up MRI between nine and 13 years later. Individuals with the highest NT-proBNP levels had significantly more silent brain infarcts and white matter lesions on the baseline MRI and more incident silent brain infarcts and white matter lesion progression on the follow-up MRI. Individuals with the highest hs-cTnT levels had more silent brain infarcts and white matter lesions on the initial MRI and more white matter lesion progression on the follow-up MRI.

Stroke symptoms or transient ischemic attack (TIA) may be strongly associated with incident cognitive impairment, researchers concluded in a study published online ahead of print June 19 in Neurology. The investigators studied 23,830 participants without cognitive impairment or history of stroke enrolled in the Reasons for Geographic and Racial Differences in Stroke Study. Subjects reported stroke symptoms and TIA every six months and were screened annually for cognitive impairment. Among Caucasians, the odds ratio for incident cognitive impairment was 2.08 for subjects reporting at least one stroke symptom or TIA, compared with those reporting no stroke symptom or TIA. Among African Americans, the odds ratio was 1.66 using the same modeling. The magnitude of impact was largest among participants with fewer traditional stroke risk factors.

—Erik Greb
Senior Associate Editor

In patients with arterial disease, low baseline diastolic blood pressure may correspond with increased progression of subcortical atrophy, researchers reported online ahead of print June 10 in JAMA Neurology. The association may not depend on subsequent change in blood pressure. Researchers measured blood pressure for 663 participants at baseline and at a mean of 3.9 years later. Change in brain parenchymal fraction, cortical gray matter fraction, and ventricular fraction were quantified as indicators of progression of global, cortical, and subcortical brain atrophy. Patients with lower baseline diastolic blood pressure or mean arterial pressure had more progression of subcortical atrophy. Of patients with higher baseline blood pressure, those with declining blood pressure over time had less progression of subcortical atrophy, compared with those with increasing blood pressure.

Diffusion tensor imaging (DTI) of the basal ganglia and cerebellum may accurately diagnose Parkinson’s disease and other movement disorders, according to a study published online ahead of print May 14 in Movement Disorders. Investigators studied 72 subjects with DTI at 3 T. The technique distinguished between controls and patients with movement disorder with 92% sensitivity and 88% specificity. DTI also distinguished between controls and patients with parkinsonism (93% sensitivity, 91% specificity), Parkinson’s disease and atypical parkinsonism (90% sensitivity, 100% specificity), Parkinson’s disease and multiple system atrophy (94% sensitivity, 100% specificity), Parkinson’s disease and progressive supranuclear palsy (87% sensitivity, 100% specificity), multiple system atrophy and progressive supranuclear palsy (90% sensitivity, 100% specificity), and Parkinson’s disease and essential tremor (92% sensitivity, 87% specificity).

Heading a soccer ball may be associated with abnormal white matter microstructure and poor neurocognitive performance, according to research published online ahead of print June 11 in Radiology. Thirty-seven amateur soccer players answered a questionnaire about heading in the previous 12 months and lifetime history of concussions. Investigators performed diffusion-tensor MRI on the players and evaluated their cognitive function. The players had headed a median of 432 times during the previous year. Heading was associated with lower fractional anisotropy (FA) at three locations in temporo-occipital white matter with a threshold that varied according to location. Heading more than 1,800 times per year was associated with lower levels of FA and poorer memory scores. Concussion history and demographic features were not significantly associated with FA or cognitive performance.

Restless legs syndrome (RLS) may entail an increased risk of mortality, independent of known risk factors, according to a study published online ahead of print June 12 in Neurology. Researchers conducted a prospective cohort study of 18,425 American men without diabetes, arthritis, or renal failure. RLS was assessed using standardized questions. During eight years of follow-up, 2,765 deaths occurred. In an age-adjusted model, RLS was associated with a 39% increased risk of mortality. The association between RLS and mortality was slightly attenuated after further adjustment for BMI, lifestyle factors, chronic conditions, sleep duration, and other sleep-related disorders. When patients with major chronic conditions (eg, cancer, high blood pressure, cardiovascular disease, and other comorbidities) were excluded, the adjusted hazard ratio for RLS was 1.92.

Patients with stroke who are about to undergo surgery can safely continue to take aspirin or warfarin in many instances, according to a guideline published in the May 28 Neurology. Researchers systematically reviewed the literature to assess evidence about the periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. Stroke patients undergoing dental procedures should routinely continue aspirin, according to the guideline. Stroke patients undergoing invasive ocular anesthesia, cataract surgery, dermatologic procedures, transrectal ultrasound–guided prostate biopsy, spinal or epidural procedures, and carpal tunnel surgery should probably continue aspirin. Stroke patients requiring warfarin should routinely continue it when undergoing dental procedures and probably continue it for dermatologic procedures. Some patients undergoing EMG, prostate procedures, inguinal herniorrhaphy, and endothermal ablation of the great saphenous vein should possibly continue warfarin.

Exposure to pesticides or solvents could be a risk factor for Parkinson’s disease, investigators concluded in the May 28 Neurology. Researchers performed a meta-analysis of prospective cohort and case-control studies that estimated the risk of Parkinson’s disease associated with exposure to pesticides or solvents. Parkinson’s disease was associated with farming, and the association between the disease and pesticides was highly significant in the studies in which Parkinson’s disease diagnosis was self-reported. In high-quality case-control studies, exposure to any pesticides, herbicides, and solvents increased the risk of Parkinson’s disease. Exposure to paraquat or maneb/mancozeb was associated with about a twofold increase in risk. Study quality was not a source of heterogeneity among prospective studies. In case-control studies, study quality was a source of heterogeneity in risk estimates for some exposures.

Atrial fibrillation may be associated with faster cognitive decline, according to a study published online ahead of print June 5 in Neurology. Researchers studied 5,150 men and women 65 or older who did not have atrial fibrillation or a history of stroke at baseline. Atrial fibrillation was identified by examining hospital discharge records and annual ECGs. A total of 552 patients (10.7%) developed incident atrial fibrillation during a mean seven years of follow-up. Mean Modified Mini-Mental State Examination (MMMSE) scores declined faster in patients with incident atrial fibrillation than in patients without atrial fibrillation. The predicted five-year decline in mean MMMSE score from age 80 to age 85 was −6.4 points for participants without atrial fibrillation and −10.3 points for participants with incident atrial fibrillation at age 80.

The level of interleukin 17F (IL-17F) in a patient with relapsing-remitting multiple sclerosis (MS) may not predict his or her response to treatment with interferon beta, according to research published online ahead of print June 3 in JAMA Neurology. Researchers analyzed serum samples from 239 randomly selected patients treated with interferon beta-1b (250 μg) for at least two years. Using clinical and MRI criteria, the investigators found that levels of IL-17F measured at baseline and month six did not correlate with lack of response to treatment after two years. Relapses and new lesions on MRI were not associated with pretreatment serum IL-17F levels. The results did not change when patients with neutralizing antibodies were excluded. Patients with levels of IL-17F higher than 200 pg/mL had poor response and clinical or radiologic activity.

Earlier treatment with thrombolytics may be associated with reduced mortality for patients with stroke, according to data published in the June 19 JAMA. Researchers analyzed data from 58,353 patients with acute ischemic stroke who were treated with t-PA within 4.5 hours of symptom onset in 1,395 hospitals. Patients’ median age was 72, 50.3% of patients were women, and median time to treatment was 144 minutes. A total of 5,142 in-hospital deaths occurred. Faster time to treatment, in 15-minute increments, was associated with reduced in-hospital mortality, reduced symptomatic intracranial hemorrhage, increased achievement of independent ambulation at discharge, and increased discharge to home. Patient factors most strongly associated with shorter time to treatment included greater stroke severity, arrival by ambulance, and arrival during regular hours.

High serum iron levels may be associated with a decreased risk of developing Parkinson’s disease, according to a study published June 4 in PLOS Medicine. Researchers investigated three polymorphisms in the genes HFE and TMPRSS6. For each polymorphism, they performed a meta-analysis of studies investigating the genetic effect on iron levels and a meta-analysis of studies investigating the genetic effect on the risk of Parkinson’s disease. Using three Mendelian randomization analyses, the investigators estimated the effect of iron on Parkinson’s disease for the three polymorphisms. Every 10 µg/dl increase in blood iron corresponded to a 3% reduction in the risk of Parkinson’s disease. Thus, increased blood iron levels may have a protective effect against Parkinson’s disease, but the underlying mechanism remains unclear, said the researchers.

Diabetes and dementia may have a bidirectional association, according to research published online ahead of print June 10 in JAMA Internal Medicine. Investigators examined 783 older adults with diabetes who were participating in a prospective population-based study. Subjects’ mean age was 74, and their baseline Modified Mini-Mental State Examination scores were 80 or higher. Approximately 47% of subjects were African American, and 47% were female. During the 12-year follow-up, 61 participants had a reported hypoglycemic event, and 148 developed dementia. Subjects who had a hypoglycemic event had a twofold increased risk for developing dementia, compared with those who did not have a hypoglycemic event. Subjects with diabetes who developed dementia had a greater risk for having a subsequent hypoglycemic event, compared with participants who did not develop dementia.

Cardiovascular biomarkers may help identify patients with subclinical cerebral injury, according to research published online ahead of print May 9 in Stroke. A total of 1,920 subjects received a brain MRI and had their levels of N-terminal brain natriuretic peptide (NT-proBNP) and cardiac troponin T (hs-cTnT) measured. Of the total group, 1,112 had a follow-up MRI between nine and 13 years later. Individuals with the highest NT-proBNP levels had significantly more silent brain infarcts and white matter lesions on the baseline MRI and more incident silent brain infarcts and white matter lesion progression on the follow-up MRI. Individuals with the highest hs-cTnT levels had more silent brain infarcts and white matter lesions on the initial MRI and more white matter lesion progression on the follow-up MRI.

Stroke symptoms or transient ischemic attack (TIA) may be strongly associated with incident cognitive impairment, researchers concluded in a study published online ahead of print June 19 in Neurology. The investigators studied 23,830 participants without cognitive impairment or history of stroke enrolled in the Reasons for Geographic and Racial Differences in Stroke Study. Subjects reported stroke symptoms and TIA every six months and were screened annually for cognitive impairment. Among Caucasians, the odds ratio for incident cognitive impairment was 2.08 for subjects reporting at least one stroke symptom or TIA, compared with those reporting no stroke symptom or TIA. Among African Americans, the odds ratio was 1.66 using the same modeling. The magnitude of impact was largest among participants with fewer traditional stroke risk factors.

—Erik Greb
Senior Associate Editor

In patients with arterial disease, low baseline diastolic blood pressure may correspond with increased progression of subcortical atrophy, researchers reported online ahead of print June 10 in JAMA Neurology. The association may not depend on subsequent change in blood pressure. Researchers measured blood pressure for 663 participants at baseline and at a mean of 3.9 years later. Change in brain parenchymal fraction, cortical gray matter fraction, and ventricular fraction were quantified as indicators of progression of global, cortical, and subcortical brain atrophy. Patients with lower baseline diastolic blood pressure or mean arterial pressure had more progression of subcortical atrophy. Of patients with higher baseline blood pressure, those with declining blood pressure over time had less progression of subcortical atrophy, compared with those with increasing blood pressure.

Diffusion tensor imaging (DTI) of the basal ganglia and cerebellum may accurately diagnose Parkinson’s disease and other movement disorders, according to a study published online ahead of print May 14 in Movement Disorders. Investigators studied 72 subjects with DTI at 3 T. The technique distinguished between controls and patients with movement disorder with 92% sensitivity and 88% specificity. DTI also distinguished between controls and patients with parkinsonism (93% sensitivity, 91% specificity), Parkinson’s disease and atypical parkinsonism (90% sensitivity, 100% specificity), Parkinson’s disease and multiple system atrophy (94% sensitivity, 100% specificity), Parkinson’s disease and progressive supranuclear palsy (87% sensitivity, 100% specificity), multiple system atrophy and progressive supranuclear palsy (90% sensitivity, 100% specificity), and Parkinson’s disease and essential tremor (92% sensitivity, 87% specificity).

Heading a soccer ball may be associated with abnormal white matter microstructure and poor neurocognitive performance, according to research published online ahead of print June 11 in Radiology. Thirty-seven amateur soccer players answered a questionnaire about heading in the previous 12 months and lifetime history of concussions. Investigators performed diffusion-tensor MRI on the players and evaluated their cognitive function. The players had headed a median of 432 times during the previous year. Heading was associated with lower fractional anisotropy (FA) at three locations in temporo-occipital white matter with a threshold that varied according to location. Heading more than 1,800 times per year was associated with lower levels of FA and poorer memory scores. Concussion history and demographic features were not significantly associated with FA or cognitive performance.

Restless legs syndrome (RLS) may entail an increased risk of mortality, independent of known risk factors, according to a study published online ahead of print June 12 in Neurology. Researchers conducted a prospective cohort study of 18,425 American men without diabetes, arthritis, or renal failure. RLS was assessed using standardized questions. During eight years of follow-up, 2,765 deaths occurred. In an age-adjusted model, RLS was associated with a 39% increased risk of mortality. The association between RLS and mortality was slightly attenuated after further adjustment for BMI, lifestyle factors, chronic conditions, sleep duration, and other sleep-related disorders. When patients with major chronic conditions (eg, cancer, high blood pressure, cardiovascular disease, and other comorbidities) were excluded, the adjusted hazard ratio for RLS was 1.92.

Patients with stroke who are about to undergo surgery can safely continue to take aspirin or warfarin in many instances, according to a guideline published in the May 28 Neurology. Researchers systematically reviewed the literature to assess evidence about the periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. Stroke patients undergoing dental procedures should routinely continue aspirin, according to the guideline. Stroke patients undergoing invasive ocular anesthesia, cataract surgery, dermatologic procedures, transrectal ultrasound–guided prostate biopsy, spinal or epidural procedures, and carpal tunnel surgery should probably continue aspirin. Stroke patients requiring warfarin should routinely continue it when undergoing dental procedures and probably continue it for dermatologic procedures. Some patients undergoing EMG, prostate procedures, inguinal herniorrhaphy, and endothermal ablation of the great saphenous vein should possibly continue warfarin.

Exposure to pesticides or solvents could be a risk factor for Parkinson’s disease, investigators concluded in the May 28 Neurology. Researchers performed a meta-analysis of prospective cohort and case-control studies that estimated the risk of Parkinson’s disease associated with exposure to pesticides or solvents. Parkinson’s disease was associated with farming, and the association between the disease and pesticides was highly significant in the studies in which Parkinson’s disease diagnosis was self-reported. In high-quality case-control studies, exposure to any pesticides, herbicides, and solvents increased the risk of Parkinson’s disease. Exposure to paraquat or maneb/mancozeb was associated with about a twofold increase in risk. Study quality was not a source of heterogeneity among prospective studies. In case-control studies, study quality was a source of heterogeneity in risk estimates for some exposures.

Atrial fibrillation may be associated with faster cognitive decline, according to a study published online ahead of print June 5 in Neurology. Researchers studied 5,150 men and women 65 or older who did not have atrial fibrillation or a history of stroke at baseline. Atrial fibrillation was identified by examining hospital discharge records and annual ECGs. A total of 552 patients (10.7%) developed incident atrial fibrillation during a mean seven years of follow-up. Mean Modified Mini-Mental State Examination (MMMSE) scores declined faster in patients with incident atrial fibrillation than in patients without atrial fibrillation. The predicted five-year decline in mean MMMSE score from age 80 to age 85 was −6.4 points for participants without atrial fibrillation and −10.3 points for participants with incident atrial fibrillation at age 80.

The level of interleukin 17F (IL-17F) in a patient with relapsing-remitting multiple sclerosis (MS) may not predict his or her response to treatment with interferon beta, according to research published online ahead of print June 3 in JAMA Neurology. Researchers analyzed serum samples from 239 randomly selected patients treated with interferon beta-1b (250 μg) for at least two years. Using clinical and MRI criteria, the investigators found that levels of IL-17F measured at baseline and month six did not correlate with lack of response to treatment after two years. Relapses and new lesions on MRI were not associated with pretreatment serum IL-17F levels. The results did not change when patients with neutralizing antibodies were excluded. Patients with levels of IL-17F higher than 200 pg/mL had poor response and clinical or radiologic activity.

Earlier treatment with thrombolytics may be associated with reduced mortality for patients with stroke, according to data published in the June 19 JAMA. Researchers analyzed data from 58,353 patients with acute ischemic stroke who were treated with t-PA within 4.5 hours of symptom onset in 1,395 hospitals. Patients’ median age was 72, 50.3% of patients were women, and median time to treatment was 144 minutes. A total of 5,142 in-hospital deaths occurred. Faster time to treatment, in 15-minute increments, was associated with reduced in-hospital mortality, reduced symptomatic intracranial hemorrhage, increased achievement of independent ambulation at discharge, and increased discharge to home. Patient factors most strongly associated with shorter time to treatment included greater stroke severity, arrival by ambulance, and arrival during regular hours.

High serum iron levels may be associated with a decreased risk of developing Parkinson’s disease, according to a study published June 4 in PLOS Medicine. Researchers investigated three polymorphisms in the genes HFE and TMPRSS6. For each polymorphism, they performed a meta-analysis of studies investigating the genetic effect on iron levels and a meta-analysis of studies investigating the genetic effect on the risk of Parkinson’s disease. Using three Mendelian randomization analyses, the investigators estimated the effect of iron on Parkinson’s disease for the three polymorphisms. Every 10 µg/dl increase in blood iron corresponded to a 3% reduction in the risk of Parkinson’s disease. Thus, increased blood iron levels may have a protective effect against Parkinson’s disease, but the underlying mechanism remains unclear, said the researchers.

Diabetes and dementia may have a bidirectional association, according to research published online ahead of print June 10 in JAMA Internal Medicine. Investigators examined 783 older adults with diabetes who were participating in a prospective population-based study. Subjects’ mean age was 74, and their baseline Modified Mini-Mental State Examination scores were 80 or higher. Approximately 47% of subjects were African American, and 47% were female. During the 12-year follow-up, 61 participants had a reported hypoglycemic event, and 148 developed dementia. Subjects who had a hypoglycemic event had a twofold increased risk for developing dementia, compared with those who did not have a hypoglycemic event. Subjects with diabetes who developed dementia had a greater risk for having a subsequent hypoglycemic event, compared with participants who did not develop dementia.

Cardiovascular biomarkers may help identify patients with subclinical cerebral injury, according to research published online ahead of print May 9 in Stroke. A total of 1,920 subjects received a brain MRI and had their levels of N-terminal brain natriuretic peptide (NT-proBNP) and cardiac troponin T (hs-cTnT) measured. Of the total group, 1,112 had a follow-up MRI between nine and 13 years later. Individuals with the highest NT-proBNP levels had significantly more silent brain infarcts and white matter lesions on the baseline MRI and more incident silent brain infarcts and white matter lesion progression on the follow-up MRI. Individuals with the highest hs-cTnT levels had more silent brain infarcts and white matter lesions on the initial MRI and more white matter lesion progression on the follow-up MRI.

Stroke symptoms or transient ischemic attack (TIA) may be strongly associated with incident cognitive impairment, researchers concluded in a study published online ahead of print June 19 in Neurology. The investigators studied 23,830 participants without cognitive impairment or history of stroke enrolled in the Reasons for Geographic and Racial Differences in Stroke Study. Subjects reported stroke symptoms and TIA every six months and were screened annually for cognitive impairment. Among Caucasians, the odds ratio for incident cognitive impairment was 2.08 for subjects reporting at least one stroke symptom or TIA, compared with those reporting no stroke symptom or TIA. Among African Americans, the odds ratio was 1.66 using the same modeling. The magnitude of impact was largest among participants with fewer traditional stroke risk factors.

—Erik Greb
Senior Associate Editor

Thadeo Catacutan, MD, sat in a ballroom at the Gaylord Resort & Convention Center in National Harbor, Md., on a sunny spring day at HM13, just thinking about his future after spending seven years as a hospitalist at Cleveland Clinic. He wondered if additional training in business administration would provide him with the advancement opportunities and professional fulfillment he sought.

“It’s been hard to determine what I really want to do,” he said. “After seven years, is this the peak? Are there other opportunities?

“I realize that if you are not going to specialize, you have to go into a leadership career track,” he said. “Some would say you can just be a clinician, but in the long term, I don’t think that is a sustainable path. You will just burn out.”

Dr. Catacutan isn’t the only one concerned. Nearly 200 physicians joined him for an HM13 breakout session titled “Career Tracks for Hospitalists.” The session provided attendees two viewpoints on career advancement: the executive pathway and the hospital leadership pathway. And although the session’s speakers demonstrated distinct routes to senior positions, there’s a shared path for each, including:

• Weighing choices carefully. The reasons for seeking a new career path are personal and not the same for everyone. Keep that in mind.
• Thinking about return on investment. Physicians should consider what they’re getting for their effort, whether that’s the cost of an advanced degree or the value of time spent volunteering on a hospital committee.
• Contemplating what you like about your job. When considering a career move, remember the adage that the grass is always greener.

“The way you get to take on leadership opportunities is by acceptance,” said session moderator Michael Guthrie, MD, MBA, executive in residence at the University of Colorado. “Say ‘yes.’ Say ‘I’m curious’ or ‘How can I make a contribution?’ You will stumble. You will make mistakes. You will be clumsy. … But it is that process that teaches you what you need to know.”

Path: Advanced Training

Michael Ruhlen, MD, MHCM, FACHE, SFHM, said he needed to know how to communicate better with the administrators he regularly met with to discuss his pediatric hospitalist program.

“I found that I wasn’t always speaking the same language when I talked to administrators about the value that hospitalists brought to their individual institutions,” he said. “No matter how hard I tried, I could always walk into a room with a master’s-prepared administrator who could absolutely prove to me that my hospitalist program would cost them far more money than it would ever be worth—and they simply could not afford it.”

To address what he calls a “knowledge deficit,” Dr. Ruhlen earned his master’s degree in health-care management from the Harvard School of Public Health in Boston. Armed with new business acumen, he rose to vice president of medical affairs at Toledo Children’s Hospital in Ohio, and even served as interim president for a short time before he became vice president and chief medical officer of Carolina HealthCare Systems in Charlotte, N.C.

“Communications, public speaking, and change management was a very big component of what we were taught,” he added, “as well as performance improvement, which is where my career has drifted.”

Dr. Ruhlen said hospitalists are perfectly positioned for leadership roles in hospitals. He also said that “institutions led by physicians appear to have better performance metrics” and that physicians “owe it to our patients to try to take back medicine.”

One thing Dr. Ruhlen wished medical training would address better is population health, a topic he became “enamored” with in business school. “It’s a very interesting body of work, interesting body of language,” he said. “I think it will be critically important as we move into a realm of significant health reform.”

Path: Quality Expertise

Greg Maynard, MD, MSC, SFHM, took a different route to hospital leadership. He didn’t seek an advanced degree in business and hasn’t bounced from one job to another climbing the corporate ladder. Instead, he’s devoted his time and energy to quality improvement (QI) as clinical professor of medicine in the division of hospital medicine at the University of California at San Diego.

Dr. Maynard encouraged hospitalists to consider becoming experts in hospital quality and patient safety, a path that has led him to national recognition. “You won’t get bored,” he said. “Your career will find you.”

Dr. Maynard, who serves as senior vice president of SHM’s Center for Healthcare Improvement and Innovation, said every QI project “seems to have its time,” and he warned hospitalists that dealing with frustration is part of the job description.

“Some projects I initiated didn’t get off the ground, no matter why I did it,” he explained. “For example, transitions of care—when we started looking at it, nobody in the hospital cared. The administrators didn’t care about discharge summaries or teachback communication strategies. They only cared when readmissions came in focus.”

He and his team needed to learn to “satisfy ourselves” and change what they could change as hospitalists. The hard part, he said, was being patient.

“We knew it was coming; we just had to wait and not get rankled,” he added. “I had to learn to not take things personally. Be patient and wait for the opportunity.”

Dr. Maynard advised hospitalists to learn to “say no, or ‘I would love to but I just can’t.’” He also said hospitalists should not be afraid to ask for help.

Return on Investment

Dr. Guthrie, who received his MBA nearly 40 years ago, said times have changed and business schools have adapted to a new economic landscape. Opportunities for physicians to receive advanced training are much greater now, with physicians earning advanced degrees in public health and health administration, as well as MBAs.

Many of the top schools offer work-friendly course schedules, including night and weekend courses and plenty of online options. Some, such as the University of Massachusetts, offer a 100% online MBA program.

Listen to Dr. Guthrie discuss his path to hospital leadership and how business schools have adapted for physicians.

Still, he warned hospitalists to consider their goals along with the time, energy, and financial commitment that post-graduate work requires.

“The investment is huge,” he said.

It’s exactly what Dr. Catacutan is contemplating. Should he go back to school, pursue leadership within the walls of his hospital and executive courses like SHM’s Leadership Academy, or should he be satisfied as a full-time clinician?

“Is it really worth my time, especially with family and kids?” he asked rhetorically. “It’s a personal decision.” TH

Richard Quinn is a freelance writer in New Jersey.

Thadeo Catacutan, MD, sat in a ballroom at the Gaylord Resort & Convention Center in National Harbor, Md., on a sunny spring day at HM13, just thinking about his future after spending seven years as a hospitalist at Cleveland Clinic. He wondered if additional training in business administration would provide him with the advancement opportunities and professional fulfillment he sought.

“It’s been hard to determine what I really want to do,” he said. “After seven years, is this the peak? Are there other opportunities?

“I realize that if you are not going to specialize, you have to go into a leadership career track,” he said. “Some would say you can just be a clinician, but in the long term, I don’t think that is a sustainable path. You will just burn out.”

Dr. Catacutan isn’t the only one concerned. Nearly 200 physicians joined him for an HM13 breakout session titled “Career Tracks for Hospitalists.” The session provided attendees two viewpoints on career advancement: the executive pathway and the hospital leadership pathway. And although the session’s speakers demonstrated distinct routes to senior positions, there’s a shared path for each, including:

• Weighing choices carefully. The reasons for seeking a new career path are personal and not the same for everyone. Keep that in mind.
• Thinking about return on investment. Physicians should consider what they’re getting for their effort, whether that’s the cost of an advanced degree or the value of time spent volunteering on a hospital committee.
• Contemplating what you like about your job. When considering a career move, remember the adage that the grass is always greener.

“The way you get to take on leadership opportunities is by acceptance,” said session moderator Michael Guthrie, MD, MBA, executive in residence at the University of Colorado. “Say ‘yes.’ Say ‘I’m curious’ or ‘How can I make a contribution?’ You will stumble. You will make mistakes. You will be clumsy. … But it is that process that teaches you what you need to know.”

Path: Advanced Training

Michael Ruhlen, MD, MHCM, FACHE, SFHM, said he needed to know how to communicate better with the administrators he regularly met with to discuss his pediatric hospitalist program.

“I found that I wasn’t always speaking the same language when I talked to administrators about the value that hospitalists brought to their individual institutions,” he said. “No matter how hard I tried, I could always walk into a room with a master’s-prepared administrator who could absolutely prove to me that my hospitalist program would cost them far more money than it would ever be worth—and they simply could not afford it.”

To address what he calls a “knowledge deficit,” Dr. Ruhlen earned his master’s degree in health-care management from the Harvard School of Public Health in Boston. Armed with new business acumen, he rose to vice president of medical affairs at Toledo Children’s Hospital in Ohio, and even served as interim president for a short time before he became vice president and chief medical officer of Carolina HealthCare Systems in Charlotte, N.C.

“Communications, public speaking, and change management was a very big component of what we were taught,” he added, “as well as performance improvement, which is where my career has drifted.”

Dr. Ruhlen said hospitalists are perfectly positioned for leadership roles in hospitals. He also said that “institutions led by physicians appear to have better performance metrics” and that physicians “owe it to our patients to try to take back medicine.”

One thing Dr. Ruhlen wished medical training would address better is population health, a topic he became “enamored” with in business school. “It’s a very interesting body of work, interesting body of language,” he said. “I think it will be critically important as we move into a realm of significant health reform.”

Path: Quality Expertise

Greg Maynard, MD, MSC, SFHM, took a different route to hospital leadership. He didn’t seek an advanced degree in business and hasn’t bounced from one job to another climbing the corporate ladder. Instead, he’s devoted his time and energy to quality improvement (QI) as clinical professor of medicine in the division of hospital medicine at the University of California at San Diego.

Dr. Maynard encouraged hospitalists to consider becoming experts in hospital quality and patient safety, a path that has led him to national recognition. “You won’t get bored,” he said. “Your career will find you.”

Dr. Maynard, who serves as senior vice president of SHM’s Center for Healthcare Improvement and Innovation, said every QI project “seems to have its time,” and he warned hospitalists that dealing with frustration is part of the job description.

“Some projects I initiated didn’t get off the ground, no matter why I did it,” he explained. “For example, transitions of care—when we started looking at it, nobody in the hospital cared. The administrators didn’t care about discharge summaries or teachback communication strategies. They only cared when readmissions came in focus.”

He and his team needed to learn to “satisfy ourselves” and change what they could change as hospitalists. The hard part, he said, was being patient.

“We knew it was coming; we just had to wait and not get rankled,” he added. “I had to learn to not take things personally. Be patient and wait for the opportunity.”

Dr. Maynard advised hospitalists to learn to “say no, or ‘I would love to but I just can’t.’” He also said hospitalists should not be afraid to ask for help.

Return on Investment

Dr. Guthrie, who received his MBA nearly 40 years ago, said times have changed and business schools have adapted to a new economic landscape. Opportunities for physicians to receive advanced training are much greater now, with physicians earning advanced degrees in public health and health administration, as well as MBAs.

Many of the top schools offer work-friendly course schedules, including night and weekend courses and plenty of online options. Some, such as the University of Massachusetts, offer a 100% online MBA program.

Listen to Dr. Guthrie discuss his path to hospital leadership and how business schools have adapted for physicians.

Still, he warned hospitalists to consider their goals along with the time, energy, and financial commitment that post-graduate work requires.

“The investment is huge,” he said.

It’s exactly what Dr. Catacutan is contemplating. Should he go back to school, pursue leadership within the walls of his hospital and executive courses like SHM’s Leadership Academy, or should he be satisfied as a full-time clinician?

“Is it really worth my time, especially with family and kids?” he asked rhetorically. “It’s a personal decision.” TH

Richard Quinn is a freelance writer in New Jersey.

Thadeo Catacutan, MD, sat in a ballroom at the Gaylord Resort & Convention Center in National Harbor, Md., on a sunny spring day at HM13, just thinking about his future after spending seven years as a hospitalist at Cleveland Clinic. He wondered if additional training in business administration would provide him with the advancement opportunities and professional fulfillment he sought.

“It’s been hard to determine what I really want to do,” he said. “After seven years, is this the peak? Are there other opportunities?

“I realize that if you are not going to specialize, you have to go into a leadership career track,” he said. “Some would say you can just be a clinician, but in the long term, I don’t think that is a sustainable path. You will just burn out.”

Dr. Catacutan isn’t the only one concerned. Nearly 200 physicians joined him for an HM13 breakout session titled “Career Tracks for Hospitalists.” The session provided attendees two viewpoints on career advancement: the executive pathway and the hospital leadership pathway. And although the session’s speakers demonstrated distinct routes to senior positions, there’s a shared path for each, including:

• Weighing choices carefully. The reasons for seeking a new career path are personal and not the same for everyone. Keep that in mind.
• Thinking about return on investment. Physicians should consider what they’re getting for their effort, whether that’s the cost of an advanced degree or the value of time spent volunteering on a hospital committee.
• Contemplating what you like about your job. When considering a career move, remember the adage that the grass is always greener.

“The way you get to take on leadership opportunities is by acceptance,” said session moderator Michael Guthrie, MD, MBA, executive in residence at the University of Colorado. “Say ‘yes.’ Say ‘I’m curious’ or ‘How can I make a contribution?’ You will stumble. You will make mistakes. You will be clumsy. … But it is that process that teaches you what you need to know.”

Path: Advanced Training

Michael Ruhlen, MD, MHCM, FACHE, SFHM, said he needed to know how to communicate better with the administrators he regularly met with to discuss his pediatric hospitalist program.

“I found that I wasn’t always speaking the same language when I talked to administrators about the value that hospitalists brought to their individual institutions,” he said. “No matter how hard I tried, I could always walk into a room with a master’s-prepared administrator who could absolutely prove to me that my hospitalist program would cost them far more money than it would ever be worth—and they simply could not afford it.”

To address what he calls a “knowledge deficit,” Dr. Ruhlen earned his master’s degree in health-care management from the Harvard School of Public Health in Boston. Armed with new business acumen, he rose to vice president of medical affairs at Toledo Children’s Hospital in Ohio, and even served as interim president for a short time before he became vice president and chief medical officer of Carolina HealthCare Systems in Charlotte, N.C.

“Communications, public speaking, and change management was a very big component of what we were taught,” he added, “as well as performance improvement, which is where my career has drifted.”

Dr. Ruhlen said hospitalists are perfectly positioned for leadership roles in hospitals. He also said that “institutions led by physicians appear to have better performance metrics” and that physicians “owe it to our patients to try to take back medicine.”

One thing Dr. Ruhlen wished medical training would address better is population health, a topic he became “enamored” with in business school. “It’s a very interesting body of work, interesting body of language,” he said. “I think it will be critically important as we move into a realm of significant health reform.”

Path: Quality Expertise

Greg Maynard, MD, MSC, SFHM, took a different route to hospital leadership. He didn’t seek an advanced degree in business and hasn’t bounced from one job to another climbing the corporate ladder. Instead, he’s devoted his time and energy to quality improvement (QI) as clinical professor of medicine in the division of hospital medicine at the University of California at San Diego.

Dr. Maynard encouraged hospitalists to consider becoming experts in hospital quality and patient safety, a path that has led him to national recognition. “You won’t get bored,” he said. “Your career will find you.”

Dr. Maynard, who serves as senior vice president of SHM’s Center for Healthcare Improvement and Innovation, said every QI project “seems to have its time,” and he warned hospitalists that dealing with frustration is part of the job description.

“Some projects I initiated didn’t get off the ground, no matter why I did it,” he explained. “For example, transitions of care—when we started looking at it, nobody in the hospital cared. The administrators didn’t care about discharge summaries or teachback communication strategies. They only cared when readmissions came in focus.”

He and his team needed to learn to “satisfy ourselves” and change what they could change as hospitalists. The hard part, he said, was being patient.

“We knew it was coming; we just had to wait and not get rankled,” he added. “I had to learn to not take things personally. Be patient and wait for the opportunity.”

Dr. Maynard advised hospitalists to learn to “say no, or ‘I would love to but I just can’t.’” He also said hospitalists should not be afraid to ask for help.

Return on Investment

Dr. Guthrie, who received his MBA nearly 40 years ago, said times have changed and business schools have adapted to a new economic landscape. Opportunities for physicians to receive advanced training are much greater now, with physicians earning advanced degrees in public health and health administration, as well as MBAs.

Many of the top schools offer work-friendly course schedules, including night and weekend courses and plenty of online options. Some, such as the University of Massachusetts, offer a 100% online MBA program.

Listen to Dr. Guthrie discuss his path to hospital leadership and how business schools have adapted for physicians.

Still, he warned hospitalists to consider their goals along with the time, energy, and financial commitment that post-graduate work requires.

“The investment is huge,” he said.

It’s exactly what Dr. Catacutan is contemplating. Should he go back to school, pursue leadership within the walls of his hospital and executive courses like SHM’s Leadership Academy, or should he be satisfied as a full-time clinician?

“Is it really worth my time, especially with family and kids?” he asked rhetorically. “It’s a personal decision.” TH

Richard Quinn is a freelance writer in New Jersey.

CHICAGO – Routine surveillance imaging does not improve clinical outcomes in patients with classic Hodgkin disease who are in first complete remission and it sharply increases costs, researchers reported at the annual meeting of the American Society of Clinical Oncology.

The team, led by Dr. Sai Ravi Pingali, retrospectively reviewed the charts of 241 adult patients who achieved a complete remission after first-line therapy.

In 68%, the treating physicians’ planned approach was routine surveillance imaging, which consisted of radiologic imaging with scans every few months, plus clinical exams and laboratory testing. In the other 32%, the planned approach was clinical surveillance, meaning that radiologic imaging was performed only if concerning signs or symptoms occurred.

The two groups had statistically indistinguishable overall survival, and in both groups, all patients experiencing relapse successfully achieved a second complete remission with salvage therapy.

In the routinely imaged group, scanning increased costs by nearly $20,000 per patient and by almost $600,000 per each relapse detected. In addition, patients were exposed to the associated radiation.

"We were unable to detect an overall survival benefit associated with routine surveillance imaging, although I have to acknowledge that our study was limited in power given the small number of deaths and relapses," commented Dr. Pingali, an oncologist with the Medical College of Wisconsin Affiliated Hospitals in Milwaukee.

"Relapses in both ... groups were effectively salvaged with autologous stem cell transplantation, arguing against a critical advantage of detection of asymptomatic relapse. Also, we need to keep in mind that the costs associated with routine surveillance imaging are significant, and it is also associated with potential risks, both in terms of radiation exposure and unnecessary work-up," he added.

"We do not feel that potential risks and costs without overall survival benefit or any other clinical benefit justify the practice of routine surveillance imaging in classical Hodgkin lymphoma patients who have achieved a complete remission after first-line therapy. We recommend that such patients be followed clinically," Dr. Pingali concluded.

Invited discussant Dr. Leo Gordon of Northwestern University in Chicago, agreed that accumulating data argue against routine imaging for surveillance in this context and noted that insurers will likely not continue to cover scans having no proven benefit. The data should prompt a revision of guidelines and reeducation of clinicians and patients, he said.

"For translational researchers and investigators and academics, I think we need to convince journal reviewers that a manuscript is acceptable if scans are not so frequent. And for industry trials, I think we need to discuss with the Food and Drug Administration the endpoint of progression-free survival and that those endpoints may not only be driven by scans but by more mundane parameters," he said—namely, the history and physical examination.

But session comoderator Dr. Gilles A. Salles of Hospices Civils de Lyon, Université Claude Bernard, France, expressed reservations, noting that the study did not provide information on how patients were allocated to groups and the time frame of relapse.

"It may be different whether relapses occur early, in the first year, or they occur later, and that may have some implications for the surveillance," he said. "I understand that you and many others jumped over the idea that we should immediately stop. A few people may think that we need more solid data, despite the provocative and quality data that were presented, to really make this jump in clinical practice. That’s my personal opinion."

Dr. Pingali and his team retrospectively reviewed the charts of adult patients who received a new diagnosis of classical Hodgkin lymphoma between 2000 and 2010 at three institutions, achieved complete remission after first-line therapy and had at least 2 years of follow-up.

The routine surveillance imaging and clinical surveillance groups had similar demographic and disease characteristics, Dr. Pingali reported. The former were significantly more likely to have received ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) and less likely to have received the Stanford V regimen as first-line therapy, and they were significantly less likely to have received radiation therapy.

With a median duration of follow-up of about 4 years, the groups did not differ significantly with respect to overall survival. "When we look at the 5-year time point, when typically the surveillance CT scans are discontinued, the curves are pretty much superimposable," he pointed out.

There were five deaths in the routine surveillance imaging group, one of which was from relapsed disease; the other deaths were from cancer, heart failure, hip fracture, and myelodysplastic syndrome. There were four deaths in the clinical surveillance group: two were from non-Hodgkin lymphoma and two from unknown causes while the patient was in confirmed remission.

All of the six patients in the routinely imaged group and all of the five patients in the clinically followed group experiencing a relapse achieved another complete remission with second-line therapy.

The mean number of scans received was 1.14 in the clinical surveillance group – usually the scan performed after first-line treatment to confirm remission, according to Dr. Pingali – and 4.25 in the routine surveillance imaging group. The ratio of scans to detected relapses was 18 vs. 124.

The extra charges incurred from scans using the routine surveillance imaging approach were $18,896/patient and $593,698/relapse.

"It is important to note that this does not include additional costs from the work-up of the false-positive scans and also the wages lost," he noted.

Dr. Pingali disclosed no relevant conflicts of interest. Dr. Gordon disclosed that he receives honoraria from Genentech and research funding from Millennium and Pharmacyclics. Dr. Salles disclosed serving as an advisor or consultant for Calistoga Pharmaceuticals, Celgene; Genentech, Janssen Pharmaceutica, and Roche. He has served as a speaker or a member of a speakers bureau and has received grants for clinical research from Celgene and Roche.

CHICAGO – Routine surveillance imaging does not improve clinical outcomes in patients with classic Hodgkin disease who are in first complete remission and it sharply increases costs, researchers reported at the annual meeting of the American Society of Clinical Oncology.

The team, led by Dr. Sai Ravi Pingali, retrospectively reviewed the charts of 241 adult patients who achieved a complete remission after first-line therapy.

In 68%, the treating physicians’ planned approach was routine surveillance imaging, which consisted of radiologic imaging with scans every few months, plus clinical exams and laboratory testing. In the other 32%, the planned approach was clinical surveillance, meaning that radiologic imaging was performed only if concerning signs or symptoms occurred.

The two groups had statistically indistinguishable overall survival, and in both groups, all patients experiencing relapse successfully achieved a second complete remission with salvage therapy.

In the routinely imaged group, scanning increased costs by nearly $20,000 per patient and by almost $600,000 per each relapse detected. In addition, patients were exposed to the associated radiation.

"We were unable to detect an overall survival benefit associated with routine surveillance imaging, although I have to acknowledge that our study was limited in power given the small number of deaths and relapses," commented Dr. Pingali, an oncologist with the Medical College of Wisconsin Affiliated Hospitals in Milwaukee.

"Relapses in both ... groups were effectively salvaged with autologous stem cell transplantation, arguing against a critical advantage of detection of asymptomatic relapse. Also, we need to keep in mind that the costs associated with routine surveillance imaging are significant, and it is also associated with potential risks, both in terms of radiation exposure and unnecessary work-up," he added.

"We do not feel that potential risks and costs without overall survival benefit or any other clinical benefit justify the practice of routine surveillance imaging in classical Hodgkin lymphoma patients who have achieved a complete remission after first-line therapy. We recommend that such patients be followed clinically," Dr. Pingali concluded.

Invited discussant Dr. Leo Gordon of Northwestern University in Chicago, agreed that accumulating data argue against routine imaging for surveillance in this context and noted that insurers will likely not continue to cover scans having no proven benefit. The data should prompt a revision of guidelines and reeducation of clinicians and patients, he said.

"For translational researchers and investigators and academics, I think we need to convince journal reviewers that a manuscript is acceptable if scans are not so frequent. And for industry trials, I think we need to discuss with the Food and Drug Administration the endpoint of progression-free survival and that those endpoints may not only be driven by scans but by more mundane parameters," he said—namely, the history and physical examination.

But session comoderator Dr. Gilles A. Salles of Hospices Civils de Lyon, Université Claude Bernard, France, expressed reservations, noting that the study did not provide information on how patients were allocated to groups and the time frame of relapse.

"It may be different whether relapses occur early, in the first year, or they occur later, and that may have some implications for the surveillance," he said. "I understand that you and many others jumped over the idea that we should immediately stop. A few people may think that we need more solid data, despite the provocative and quality data that were presented, to really make this jump in clinical practice. That’s my personal opinion."

Dr. Pingali and his team retrospectively reviewed the charts of adult patients who received a new diagnosis of classical Hodgkin lymphoma between 2000 and 2010 at three institutions, achieved complete remission after first-line therapy and had at least 2 years of follow-up.

The routine surveillance imaging and clinical surveillance groups had similar demographic and disease characteristics, Dr. Pingali reported. The former were significantly more likely to have received ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) and less likely to have received the Stanford V regimen as first-line therapy, and they were significantly less likely to have received radiation therapy.

With a median duration of follow-up of about 4 years, the groups did not differ significantly with respect to overall survival. "When we look at the 5-year time point, when typically the surveillance CT scans are discontinued, the curves are pretty much superimposable," he pointed out.

There were five deaths in the routine surveillance imaging group, one of which was from relapsed disease; the other deaths were from cancer, heart failure, hip fracture, and myelodysplastic syndrome. There were four deaths in the clinical surveillance group: two were from non-Hodgkin lymphoma and two from unknown causes while the patient was in confirmed remission.

All of the six patients in the routinely imaged group and all of the five patients in the clinically followed group experiencing a relapse achieved another complete remission with second-line therapy.

The mean number of scans received was 1.14 in the clinical surveillance group – usually the scan performed after first-line treatment to confirm remission, according to Dr. Pingali – and 4.25 in the routine surveillance imaging group. The ratio of scans to detected relapses was 18 vs. 124.

The extra charges incurred from scans using the routine surveillance imaging approach were $18,896/patient and $593,698/relapse.

"It is important to note that this does not include additional costs from the work-up of the false-positive scans and also the wages lost," he noted.

Dr. Pingali disclosed no relevant conflicts of interest. Dr. Gordon disclosed that he receives honoraria from Genentech and research funding from Millennium and Pharmacyclics. Dr. Salles disclosed serving as an advisor or consultant for Calistoga Pharmaceuticals, Celgene; Genentech, Janssen Pharmaceutica, and Roche. He has served as a speaker or a member of a speakers bureau and has received grants for clinical research from Celgene and Roche.

CHICAGO – Routine surveillance imaging does not improve clinical outcomes in patients with classic Hodgkin disease who are in first complete remission and it sharply increases costs, researchers reported at the annual meeting of the American Society of Clinical Oncology.

The team, led by Dr. Sai Ravi Pingali, retrospectively reviewed the charts of 241 adult patients who achieved a complete remission after first-line therapy.

In 68%, the treating physicians’ planned approach was routine surveillance imaging, which consisted of radiologic imaging with scans every few months, plus clinical exams and laboratory testing. In the other 32%, the planned approach was clinical surveillance, meaning that radiologic imaging was performed only if concerning signs or symptoms occurred.

The two groups had statistically indistinguishable overall survival, and in both groups, all patients experiencing relapse successfully achieved a second complete remission with salvage therapy.

In the routinely imaged group, scanning increased costs by nearly $20,000 per patient and by almost $600,000 per each relapse detected. In addition, patients were exposed to the associated radiation.

"We were unable to detect an overall survival benefit associated with routine surveillance imaging, although I have to acknowledge that our study was limited in power given the small number of deaths and relapses," commented Dr. Pingali, an oncologist with the Medical College of Wisconsin Affiliated Hospitals in Milwaukee.

"Relapses in both ... groups were effectively salvaged with autologous stem cell transplantation, arguing against a critical advantage of detection of asymptomatic relapse. Also, we need to keep in mind that the costs associated with routine surveillance imaging are significant, and it is also associated with potential risks, both in terms of radiation exposure and unnecessary work-up," he added.

"We do not feel that potential risks and costs without overall survival benefit or any other clinical benefit justify the practice of routine surveillance imaging in classical Hodgkin lymphoma patients who have achieved a complete remission after first-line therapy. We recommend that such patients be followed clinically," Dr. Pingali concluded.

Invited discussant Dr. Leo Gordon of Northwestern University in Chicago, agreed that accumulating data argue against routine imaging for surveillance in this context and noted that insurers will likely not continue to cover scans having no proven benefit. The data should prompt a revision of guidelines and reeducation of clinicians and patients, he said.

"For translational researchers and investigators and academics, I think we need to convince journal reviewers that a manuscript is acceptable if scans are not so frequent. And for industry trials, I think we need to discuss with the Food and Drug Administration the endpoint of progression-free survival and that those endpoints may not only be driven by scans but by more mundane parameters," he said—namely, the history and physical examination.

But session comoderator Dr. Gilles A. Salles of Hospices Civils de Lyon, Université Claude Bernard, France, expressed reservations, noting that the study did not provide information on how patients were allocated to groups and the time frame of relapse.

"It may be different whether relapses occur early, in the first year, or they occur later, and that may have some implications for the surveillance," he said. "I understand that you and many others jumped over the idea that we should immediately stop. A few people may think that we need more solid data, despite the provocative and quality data that were presented, to really make this jump in clinical practice. That’s my personal opinion."

Dr. Pingali and his team retrospectively reviewed the charts of adult patients who received a new diagnosis of classical Hodgkin lymphoma between 2000 and 2010 at three institutions, achieved complete remission after first-line therapy and had at least 2 years of follow-up.

The routine surveillance imaging and clinical surveillance groups had similar demographic and disease characteristics, Dr. Pingali reported. The former were significantly more likely to have received ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) and less likely to have received the Stanford V regimen as first-line therapy, and they were significantly less likely to have received radiation therapy.

With a median duration of follow-up of about 4 years, the groups did not differ significantly with respect to overall survival. "When we look at the 5-year time point, when typically the surveillance CT scans are discontinued, the curves are pretty much superimposable," he pointed out.

There were five deaths in the routine surveillance imaging group, one of which was from relapsed disease; the other deaths were from cancer, heart failure, hip fracture, and myelodysplastic syndrome. There were four deaths in the clinical surveillance group: two were from non-Hodgkin lymphoma and two from unknown causes while the patient was in confirmed remission.

All of the six patients in the routinely imaged group and all of the five patients in the clinically followed group experiencing a relapse achieved another complete remission with second-line therapy.

The mean number of scans received was 1.14 in the clinical surveillance group – usually the scan performed after first-line treatment to confirm remission, according to Dr. Pingali – and 4.25 in the routine surveillance imaging group. The ratio of scans to detected relapses was 18 vs. 124.

The extra charges incurred from scans using the routine surveillance imaging approach were $18,896/patient and $593,698/relapse.

"It is important to note that this does not include additional costs from the work-up of the false-positive scans and also the wages lost," he noted.

Dr. Pingali disclosed no relevant conflicts of interest. Dr. Gordon disclosed that he receives honoraria from Genentech and research funding from Millennium and Pharmacyclics. Dr. Salles disclosed serving as an advisor or consultant for Calistoga Pharmaceuticals, Celgene; Genentech, Janssen Pharmaceutica, and Roche. He has served as a speaker or a member of a speakers bureau and has received grants for clinical research from Celgene and Roche.

Photo by Piotr Bodzek

AMSTERDAM—A recombinant factor IX Fc fusion protein (rFIXFc) can control bleeding among hemophilia B patients undergoing major surgery, according to data from the B-LONG study presented at ISTH 2013.

The goal of the phase 3 B-LONG study was to evaluate the safety, efficacy, and pharmacokinetics (PK) of rFIXFc among male patients with hemophilia B.

Previously released data from the study suggested rFIXFc can safely prevent bleeding in these patients, and the product stays in the body more than twice as long as the recombinant factor IX therapy BeneFIX.

At ISTH 2013, Jerry Powell, MD, of the University of California at Davis, presented an analysis of B-LONG data that demonstrated rFIXFc’s effects among hemophilia B patients who underwent major surgery (e-Poster PA 2.07-4).

The B-LONG study was sponsored by Biogen Idec and Sobi, the companies developing rFIXFc (also known as eftrenonacog alfa) as Alprolix.

The study included 123 male subjects with severe hemophilia B (≤2 IU/dL [2%] endogenous FIX). Patients were 12 years of age or older They had no current or previous FIX inhibitors and a history of 100 or more documented prior exposure days to FIX products.

Patients received rFIXFc in 1 of 4 treatment arms:

1. Weekly prophylaxis starting at 50 IU/kg, with PK-driven dose adjustments  (n=63)
2. Individualized interval prophylaxis starting at 100 IU/kg every 10 days, with PK-driven interval adjustments (n=29)
3. On-demand treatment at 20 IU/kg to 100 IU/kg (n=27)
4. Perioperative management (n=12, including 8 from arms 1-3).

The patients who required major surgery were placed in arm 4. Investigators and surgeons decided upon treatment for these patients based on considerations of their rFIXFc PK profile, the type of planned surgery, and the patients’ clinical status.

The 12 patients underwent a total of 14 major surgeries, including arthroscopic meniscectomy of knee (n=1), arthroscopic ankle fusion (n=1), knee replacements (n=5), and other (n=7).

The investigators/surgeons rated hemostasis as “excellent” in 13 of the surgeries and “good” for 1 procedure.

The median estimated blood loss was 65.5 mL (range, 0.0 to 300.0 mL) during surgery and 0.0 mL (range, 0.0 to 500 mL) after surgery. None of the patients required blood transfusions during surgery, but 2 patients received transfusions postoperatively.

In most of the surgeries—85.7%—patients required a single injection of rFIXFc to maintain hemostasis during the operation. The median dose was 90.9 IU/kg per injection.

Most patients required 1 to 2 injections of rFIXFc the day before and the day of surgery. And most patients required 2 to 3 injections from days 1 to 3 after surgery. So the median rFIXFc consumption was 146.1 IU/kg on the day of surgery, 164.6 IU/kg from days 1 to 3 after surgery, and 277.1 IU/kg for days 4 to 14 after surgery.

A majority of patients—83.3% (10/12)—experienced 1 or more adverse events related to treatment. Three patients experienced 6 adverse events, but these were resolved, and investigators said they were unrelated to rFIXFc treatment.

Additional analyses of B-LONG data were presented at ISTH 2013, including an analysis of rFIXFc in the treatment of bleeding episodes and a PK analysis of rFIXFc.

Photo by Piotr Bodzek

AMSTERDAM—A recombinant factor IX Fc fusion protein (rFIXFc) can control bleeding among hemophilia B patients undergoing major surgery, according to data from the B-LONG study presented at ISTH 2013.

The goal of the phase 3 B-LONG study was to evaluate the safety, efficacy, and pharmacokinetics (PK) of rFIXFc among male patients with hemophilia B.

Previously released data from the study suggested rFIXFc can safely prevent bleeding in these patients, and the product stays in the body more than twice as long as the recombinant factor IX therapy BeneFIX.

At ISTH 2013, Jerry Powell, MD, of the University of California at Davis, presented an analysis of B-LONG data that demonstrated rFIXFc’s effects among hemophilia B patients who underwent major surgery (e-Poster PA 2.07-4).

The B-LONG study was sponsored by Biogen Idec and Sobi, the companies developing rFIXFc (also known as eftrenonacog alfa) as Alprolix.

The study included 123 male subjects with severe hemophilia B (≤2 IU/dL [2%] endogenous FIX). Patients were 12 years of age or older They had no current or previous FIX inhibitors and a history of 100 or more documented prior exposure days to FIX products.

Patients received rFIXFc in 1 of 4 treatment arms:

1. Weekly prophylaxis starting at 50 IU/kg, with PK-driven dose adjustments  (n=63)
2. Individualized interval prophylaxis starting at 100 IU/kg every 10 days, with PK-driven interval adjustments (n=29)
3. On-demand treatment at 20 IU/kg to 100 IU/kg (n=27)
4. Perioperative management (n=12, including 8 from arms 1-3).

The patients who required major surgery were placed in arm 4. Investigators and surgeons decided upon treatment for these patients based on considerations of their rFIXFc PK profile, the type of planned surgery, and the patients’ clinical status.

The 12 patients underwent a total of 14 major surgeries, including arthroscopic meniscectomy of knee (n=1), arthroscopic ankle fusion (n=1), knee replacements (n=5), and other (n=7).

The investigators/surgeons rated hemostasis as “excellent” in 13 of the surgeries and “good” for 1 procedure.

The median estimated blood loss was 65.5 mL (range, 0.0 to 300.0 mL) during surgery and 0.0 mL (range, 0.0 to 500 mL) after surgery. None of the patients required blood transfusions during surgery, but 2 patients received transfusions postoperatively.

In most of the surgeries—85.7%—patients required a single injection of rFIXFc to maintain hemostasis during the operation. The median dose was 90.9 IU/kg per injection.

Most patients required 1 to 2 injections of rFIXFc the day before and the day of surgery. And most patients required 2 to 3 injections from days 1 to 3 after surgery. So the median rFIXFc consumption was 146.1 IU/kg on the day of surgery, 164.6 IU/kg from days 1 to 3 after surgery, and 277.1 IU/kg for days 4 to 14 after surgery.

A majority of patients—83.3% (10/12)—experienced 1 or more adverse events related to treatment. Three patients experienced 6 adverse events, but these were resolved, and investigators said they were unrelated to rFIXFc treatment.

Additional analyses of B-LONG data were presented at ISTH 2013, including an analysis of rFIXFc in the treatment of bleeding episodes and a PK analysis of rFIXFc.

Photo by Piotr Bodzek

AMSTERDAM—A recombinant factor IX Fc fusion protein (rFIXFc) can control bleeding among hemophilia B patients undergoing major surgery, according to data from the B-LONG study presented at ISTH 2013.

The goal of the phase 3 B-LONG study was to evaluate the safety, efficacy, and pharmacokinetics (PK) of rFIXFc among male patients with hemophilia B.

Previously released data from the study suggested rFIXFc can safely prevent bleeding in these patients, and the product stays in the body more than twice as long as the recombinant factor IX therapy BeneFIX.

At ISTH 2013, Jerry Powell, MD, of the University of California at Davis, presented an analysis of B-LONG data that demonstrated rFIXFc’s effects among hemophilia B patients who underwent major surgery (e-Poster PA 2.07-4).

The B-LONG study was sponsored by Biogen Idec and Sobi, the companies developing rFIXFc (also known as eftrenonacog alfa) as Alprolix.

The study included 123 male subjects with severe hemophilia B (≤2 IU/dL [2%] endogenous FIX). Patients were 12 years of age or older They had no current or previous FIX inhibitors and a history of 100 or more documented prior exposure days to FIX products.

Patients received rFIXFc in 1 of 4 treatment arms:

1. Weekly prophylaxis starting at 50 IU/kg, with PK-driven dose adjustments  (n=63)
2. Individualized interval prophylaxis starting at 100 IU/kg every 10 days, with PK-driven interval adjustments (n=29)
3. On-demand treatment at 20 IU/kg to 100 IU/kg (n=27)
4. Perioperative management (n=12, including 8 from arms 1-3).

The patients who required major surgery were placed in arm 4. Investigators and surgeons decided upon treatment for these patients based on considerations of their rFIXFc PK profile, the type of planned surgery, and the patients’ clinical status.

The 12 patients underwent a total of 14 major surgeries, including arthroscopic meniscectomy of knee (n=1), arthroscopic ankle fusion (n=1), knee replacements (n=5), and other (n=7).

The investigators/surgeons rated hemostasis as “excellent” in 13 of the surgeries and “good” for 1 procedure.

The median estimated blood loss was 65.5 mL (range, 0.0 to 300.0 mL) during surgery and 0.0 mL (range, 0.0 to 500 mL) after surgery. None of the patients required blood transfusions during surgery, but 2 patients received transfusions postoperatively.

In most of the surgeries—85.7%—patients required a single injection of rFIXFc to maintain hemostasis during the operation. The median dose was 90.9 IU/kg per injection.

Most patients required 1 to 2 injections of rFIXFc the day before and the day of surgery. And most patients required 2 to 3 injections from days 1 to 3 after surgery. So the median rFIXFc consumption was 146.1 IU/kg on the day of surgery, 164.6 IU/kg from days 1 to 3 after surgery, and 277.1 IU/kg for days 4 to 14 after surgery.

A majority of patients—83.3% (10/12)—experienced 1 or more adverse events related to treatment. Three patients experienced 6 adverse events, but these were resolved, and investigators said they were unrelated to rFIXFc treatment.

Additional analyses of B-LONG data were presented at ISTH 2013, including an analysis of rFIXFc in the treatment of bleeding episodes and a PK analysis of rFIXFc.

Many oncologists remember the storied history of homoharringtonine (HHT) and wonder whatever happened to it. HHT showed initial promise for myeloid leukemias, particularly for chronic myelogenous leukemia (CML) where it seemed to induce more cytogenetic remissions than did interferon alpha.1 Unfortunately for HHT investigators, but fortunately for everybody else, these studies coincided with those being done with imatinib. The phenomenal introduction of imatinib contributed to the shelving of HHT in the mid to late 1990s.2 As is often the case, though, imatinib is not perfect. Some patients with CML develop resistance and approximately half of these do so through the acquisition of binding site mutations. One mutation in particular, T315I, rendered patients with CML resistant to all available tyrosine kinase inhibitors (TKI). In the meantime, a semisynthetic version of HHT, omacetaxine mepesuccinate, was developed. With the help of partners in industry, investigators at MD Anderson Cancer Center initiated new studies of omacetaxine in TKI resistant CML patients. Among 62 CML patients with a T315I mutation, complete hematologic response was achieved in 77% with median response duration of 9.1 months.3 Further, cytogenetic response was also achieved in a portion of patients, complete in 16%. These data prompted application for approval by the Food and Drug Administration, but were rejected for lack of a standardized test for T315I mutations. The additional data presented in the Community Translations article on page 194 formed the basis of a second application, this time for an indication in patients with CML resistant to 2 or more TKIs.

Many oncologists remember the storied history of homoharringtonine (HHT) and wonder whatever happened to it. HHT showed initial promise for myeloid leukemias, particularly for chronic myelogenous leukemia (CML) where it seemed to induce more cytogenetic remissions than did interferon alpha.1 Unfortunately for HHT investigators, but fortunately for everybody else, these studies coincided with those being done with imatinib. The phenomenal introduction of imatinib contributed to the shelving of HHT in the mid to late 1990s.2 As is often the case, though, imatinib is not perfect. Some patients with CML develop resistance and approximately half of these do so through the acquisition of binding site mutations. One mutation in particular, T315I, rendered patients with CML resistant to all available tyrosine kinase inhibitors (TKI). In the meantime, a semisynthetic version of HHT, omacetaxine mepesuccinate, was developed. With the help of partners in industry, investigators at MD Anderson Cancer Center initiated new studies of omacetaxine in TKI resistant CML patients. Among 62 CML patients with a T315I mutation, complete hematologic response was achieved in 77% with median response duration of 9.1 months.3 Further, cytogenetic response was also achieved in a portion of patients, complete in 16%. These data prompted application for approval by the Food and Drug Administration, but were rejected for lack of a standardized test for T315I mutations. The additional data presented in the Community Translations article on page 194 formed the basis of a second application, this time for an indication in patients with CML resistant to 2 or more TKIs.

Many oncologists remember the storied history of homoharringtonine (HHT) and wonder whatever happened to it. HHT showed initial promise for myeloid leukemias, particularly for chronic myelogenous leukemia (CML) where it seemed to induce more cytogenetic remissions than did interferon alpha.1 Unfortunately for HHT investigators, but fortunately for everybody else, these studies coincided with those being done with imatinib. The phenomenal introduction of imatinib contributed to the shelving of HHT in the mid to late 1990s.2 As is often the case, though, imatinib is not perfect. Some patients with CML develop resistance and approximately half of these do so through the acquisition of binding site mutations. One mutation in particular, T315I, rendered patients with CML resistant to all available tyrosine kinase inhibitors (TKI). In the meantime, a semisynthetic version of HHT, omacetaxine mepesuccinate, was developed. With the help of partners in industry, investigators at MD Anderson Cancer Center initiated new studies of omacetaxine in TKI resistant CML patients. Among 62 CML patients with a T315I mutation, complete hematologic response was achieved in 77% with median response duration of 9.1 months.3 Further, cytogenetic response was also achieved in a portion of patients, complete in 16%. These data prompted application for approval by the Food and Drug Administration, but were rejected for lack of a standardized test for T315I mutations. The additional data presented in the Community Translations article on page 194 formed the basis of a second application, this time for an indication in patients with CML resistant to 2 or more TKIs.

With this issue of COMMUNITY ONCOLOGY, memories of this year’s annual meeting of the American Society of Clinical Oncology in Chicago are starting to fade, but we are still trying to make sense of the wealth of data that was presented there. I found a number of the presentations particularly noteworthy and some of the findings likely to have an impact on how we practice. The aTTom trial1 by a group of British researchers was presented at the plenary session and dovetailed nicely with the ATLAS trial² findings that were presented at last year’s San Antonio Breast Cancer Symposium. Both trials examined 5 and 10 years of adjuvant tamoxifen in women with early stage, hormone-positive breast cancer, and findings from both trials showed reductions in recurrence, breast cancer mortality, and overall mortality in women who remained on tamoxifen to year 10. Two presentations examined frequency of scanning in Hodgkin and non-Hodgkin lymphoma and both groups of researchers concluded what many of us have often suspected – that we overscan, and that clinical surveillance is an adequate strategy for detecting recurrence. One study showed that most diffuse large B-cell lymphoma relapses were found by detection of symptoms during a physical exam, lab abnormalities, or even the patients themselves, and that routine surveillance scans did not add much to the detection of relapse.³ Findings from a second study showed that routine surveillance did not result in any survival advantage in patients with classical Hodgkin lymphoma who had achieved complete remission.⁴

With this issue of COMMUNITY ONCOLOGY, memories of this year’s annual meeting of the American Society of Clinical Oncology in Chicago are starting to fade, but we are still trying to make sense of the wealth of data that was presented there. I found a number of the presentations particularly noteworthy and some of the findings likely to have an impact on how we practice. The aTTom trial1 by a group of British researchers was presented at the plenary session and dovetailed nicely with the ATLAS trial² findings that were presented at last year’s San Antonio Breast Cancer Symposium. Both trials examined 5 and 10 years of adjuvant tamoxifen in women with early stage, hormone-positive breast cancer, and findings from both trials showed reductions in recurrence, breast cancer mortality, and overall mortality in women who remained on tamoxifen to year 10. Two presentations examined frequency of scanning in Hodgkin and non-Hodgkin lymphoma and both groups of researchers concluded what many of us have often suspected – that we overscan, and that clinical surveillance is an adequate strategy for detecting recurrence. One study showed that most diffuse large B-cell lymphoma relapses were found by detection of symptoms during a physical exam, lab abnormalities, or even the patients themselves, and that routine surveillance scans did not add much to the detection of relapse.³ Findings from a second study showed that routine surveillance did not result in any survival advantage in patients with classical Hodgkin lymphoma who had achieved complete remission.⁴

With this issue of COMMUNITY ONCOLOGY, memories of this year’s annual meeting of the American Society of Clinical Oncology in Chicago are starting to fade, but we are still trying to make sense of the wealth of data that was presented there. I found a number of the presentations particularly noteworthy and some of the findings likely to have an impact on how we practice. The aTTom trial1 by a group of British researchers was presented at the plenary session and dovetailed nicely with the ATLAS trial² findings that were presented at last year’s San Antonio Breast Cancer Symposium. Both trials examined 5 and 10 years of adjuvant tamoxifen in women with early stage, hormone-positive breast cancer, and findings from both trials showed reductions in recurrence, breast cancer mortality, and overall mortality in women who remained on tamoxifen to year 10. Two presentations examined frequency of scanning in Hodgkin and non-Hodgkin lymphoma and both groups of researchers concluded what many of us have often suspected – that we overscan, and that clinical surveillance is an adequate strategy for detecting recurrence. One study showed that most diffuse large B-cell lymphoma relapses were found by detection of symptoms during a physical exam, lab abnormalities, or even the patients themselves, and that routine surveillance scans did not add much to the detection of relapse.³ Findings from a second study showed that routine surveillance did not result in any survival advantage in patients with classical Hodgkin lymphoma who had achieved complete remission.⁴

A new study shows that in patients with acute ischemic stroke, every 15 minutes counts when talking about the time it takes to begin intravenous tissue-type plasminogen activator (tPA) therapy.

According to a report in JAMA, patients who received tPA treatment within 4.5 hours of symptom onset and had faster onset to treatment (OTT) had reduced in-hospital mortality and symptomatic intracranial hemorrhage rates (odds ratio for each, 0.96). Each 15-minute reduction in OTT also increased rates of independent ambulation at discharge and discharge to the home.

"This study emphasizes and characterizes better than before the fundamental importance of rapid start of thrombolytic therapy for acute ischemic stroke," says lead author Jeffrey Saver, MD, professor of neurology at the Geffen School of Medicine at the University of California at Los Angeles (UCLA) and director of the UCLA Stroke Center. "[For] every 15-minute delay of start of therapy, two fewer of out of 100 patients benefit. And this means that hospital systems need to be optimized to ensure that the target of door-to-needle time for start of tPA being under 60 minutes is achieved more often."

Dr. Saver says door-to-needle times under one hour have improved in recent years to nearly 50% from 25%, but hospitals can do better.

Recommended steps to improve that figure include having ambulances provide pre-arrival notification of stroke patients, having everyone on a stroke/hospitalist team paged at once to prepare all physicians who would potentially interact with the patients, premixing thrombolytic drugs to allow for quicker use, and having a data feedback system so institutions can figure out where the obstacles are to achieving improved performance.

"This is the type of system change that occurs by evolution, not revolution," Dr. Saver adds. "You need to bring your team together, you need physician champions to take the lead, and then you need to slowly drive system change based on the data in your institution. This is not an easy task, but it’s the type of task that hospitalists are perfect for."

Visit our website for more information on stroke treatments.

A new study shows that in patients with acute ischemic stroke, every 15 minutes counts when talking about the time it takes to begin intravenous tissue-type plasminogen activator (tPA) therapy.

According to a report in JAMA, patients who received tPA treatment within 4.5 hours of symptom onset and had faster onset to treatment (OTT) had reduced in-hospital mortality and symptomatic intracranial hemorrhage rates (odds ratio for each, 0.96). Each 15-minute reduction in OTT also increased rates of independent ambulation at discharge and discharge to the home.

"This study emphasizes and characterizes better than before the fundamental importance of rapid start of thrombolytic therapy for acute ischemic stroke," says lead author Jeffrey Saver, MD, professor of neurology at the Geffen School of Medicine at the University of California at Los Angeles (UCLA) and director of the UCLA Stroke Center. "[For] every 15-minute delay of start of therapy, two fewer of out of 100 patients benefit. And this means that hospital systems need to be optimized to ensure that the target of door-to-needle time for start of tPA being under 60 minutes is achieved more often."

Dr. Saver says door-to-needle times under one hour have improved in recent years to nearly 50% from 25%, but hospitals can do better.

Recommended steps to improve that figure include having ambulances provide pre-arrival notification of stroke patients, having everyone on a stroke/hospitalist team paged at once to prepare all physicians who would potentially interact with the patients, premixing thrombolytic drugs to allow for quicker use, and having a data feedback system so institutions can figure out where the obstacles are to achieving improved performance.

"This is the type of system change that occurs by evolution, not revolution," Dr. Saver adds. "You need to bring your team together, you need physician champions to take the lead, and then you need to slowly drive system change based on the data in your institution. This is not an easy task, but it’s the type of task that hospitalists are perfect for."

Visit our website for more information on stroke treatments.

A new study shows that in patients with acute ischemic stroke, every 15 minutes counts when talking about the time it takes to begin intravenous tissue-type plasminogen activator (tPA) therapy.

According to a report in JAMA, patients who received tPA treatment within 4.5 hours of symptom onset and had faster onset to treatment (OTT) had reduced in-hospital mortality and symptomatic intracranial hemorrhage rates (odds ratio for each, 0.96). Each 15-minute reduction in OTT also increased rates of independent ambulation at discharge and discharge to the home.

"This study emphasizes and characterizes better than before the fundamental importance of rapid start of thrombolytic therapy for acute ischemic stroke," says lead author Jeffrey Saver, MD, professor of neurology at the Geffen School of Medicine at the University of California at Los Angeles (UCLA) and director of the UCLA Stroke Center. "[For] every 15-minute delay of start of therapy, two fewer of out of 100 patients benefit. And this means that hospital systems need to be optimized to ensure that the target of door-to-needle time for start of tPA being under 60 minutes is achieved more often."

Dr. Saver says door-to-needle times under one hour have improved in recent years to nearly 50% from 25%, but hospitals can do better.

Recommended steps to improve that figure include having ambulances provide pre-arrival notification of stroke patients, having everyone on a stroke/hospitalist team paged at once to prepare all physicians who would potentially interact with the patients, premixing thrombolytic drugs to allow for quicker use, and having a data feedback system so institutions can figure out where the obstacles are to achieving improved performance.

"This is the type of system change that occurs by evolution, not revolution," Dr. Saver adds. "You need to bring your team together, you need physician champions to take the lead, and then you need to slowly drive system change based on the data in your institution. This is not an easy task, but it’s the type of task that hospitalists are perfect for."

Visit our website for more information on stroke treatments.

The Center for Medicare & Medicaid Innovation's Rick Gilfillan, MD, will be leaving at the end of June, just as the organization prepares to start accepting round-two grant applications for up to $1 billion in Health Care Innovation Awards. Replacing him as acting director will be Patrick Conway, MD, MSc, FAAP, SFHM, a practicing pediatric hospitalist, former director of hospital medicine at Cincinnati Children's Hospital, and HM13 keynote speaker.

Dr. Conway will continue in his current role as CMS' chief medical officer.

"We applaud Patrick Conway's appointment to the Center for Medicare & Medicaid Innovation," says SHM President Eric Howell, MD, SFHM. "His work, compassion, and vision are tremendous validations of the hospitalist model as both a change agent and as a career path. Patients across the country will be the true beneficiaries of his new work.

"Hospitalists should continue to look toward the CMS Innovation Center as a leader in transforming healthcare."

The center was created by the 2010 Affordable Care Act to offer solutions to healthcare cost and delivery problems. Its first round of 107 innovations awards, averaging $8.4 million each over three years, was announced in 2012 and included several that focused on preventing hospitalizations, avoidable rehospitalizations, and ED visits. One award went to David Meltzer, MD, PhD, FHM, of the University of Chicago to test a model in which the same doctor would see selected high-risk patients both in and out of the hospital.

Round two "provides hospitalists—who have an exceptionally broad perspective—with a unique opportunity to share new approaches to delivering the best patient care at an affordable cost," Dr. Conway told The Hospitalist.

Visit our website for more information on CMS Innovation Center initiatives.

The Center for Medicare & Medicaid Innovation's Rick Gilfillan, MD, will be leaving at the end of June, just as the organization prepares to start accepting round-two grant applications for up to $1 billion in Health Care Innovation Awards. Replacing him as acting director will be Patrick Conway, MD, MSc, FAAP, SFHM, a practicing pediatric hospitalist, former director of hospital medicine at Cincinnati Children's Hospital, and HM13 keynote speaker.

Dr. Conway will continue in his current role as CMS' chief medical officer.

"We applaud Patrick Conway's appointment to the Center for Medicare & Medicaid Innovation," says SHM President Eric Howell, MD, SFHM. "His work, compassion, and vision are tremendous validations of the hospitalist model as both a change agent and as a career path. Patients across the country will be the true beneficiaries of his new work.

"Hospitalists should continue to look toward the CMS Innovation Center as a leader in transforming healthcare."

The center was created by the 2010 Affordable Care Act to offer solutions to healthcare cost and delivery problems. Its first round of 107 innovations awards, averaging $8.4 million each over three years, was announced in 2012 and included several that focused on preventing hospitalizations, avoidable rehospitalizations, and ED visits. One award went to David Meltzer, MD, PhD, FHM, of the University of Chicago to test a model in which the same doctor would see selected high-risk patients both in and out of the hospital.

Round two "provides hospitalists—who have an exceptionally broad perspective—with a unique opportunity to share new approaches to delivering the best patient care at an affordable cost," Dr. Conway told The Hospitalist.

Visit our website for more information on CMS Innovation Center initiatives.

The Center for Medicare & Medicaid Innovation's Rick Gilfillan, MD, will be leaving at the end of June, just as the organization prepares to start accepting round-two grant applications for up to $1 billion in Health Care Innovation Awards. Replacing him as acting director will be Patrick Conway, MD, MSc, FAAP, SFHM, a practicing pediatric hospitalist, former director of hospital medicine at Cincinnati Children's Hospital, and HM13 keynote speaker.

Dr. Conway will continue in his current role as CMS' chief medical officer.

"We applaud Patrick Conway's appointment to the Center for Medicare & Medicaid Innovation," says SHM President Eric Howell, MD, SFHM. "His work, compassion, and vision are tremendous validations of the hospitalist model as both a change agent and as a career path. Patients across the country will be the true beneficiaries of his new work.

"Hospitalists should continue to look toward the CMS Innovation Center as a leader in transforming healthcare."

The center was created by the 2010 Affordable Care Act to offer solutions to healthcare cost and delivery problems. Its first round of 107 innovations awards, averaging $8.4 million each over three years, was announced in 2012 and included several that focused on preventing hospitalizations, avoidable rehospitalizations, and ED visits. One award went to David Meltzer, MD, PhD, FHM, of the University of Chicago to test a model in which the same doctor would see selected high-risk patients both in and out of the hospital.

Round two "provides hospitalists—who have an exceptionally broad perspective—with a unique opportunity to share new approaches to delivering the best patient care at an affordable cost," Dr. Conway told The Hospitalist.

Visit our website for more information on CMS Innovation Center initiatives.